Alexandre Fagnan

Alexandre Fagnan

Auto-generated profile, based on publicly available information

Alexandre Fagnan

Gustave Roussy cancer center, Université Paris Diderot, Université Paris-Sud, OPALE Carnot Institute, PEDIAC consortium

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2020 in Blood
Verified
Journal Article
Open access
PDF file
AFAlexandre Fagnan
Alexandre Fagnan
FBFrederik Otzen Bagger
Frederik Otzen Bagger
MPMaria-Riera Piqué-Borràs
Maria-Riera Piqué-Borràs
CICathy Ignacimouttou
Cathy Ignacimouttou
ACAlexis Caulier
Alexis Caulier
TMThomas Mercher
Thomas Mercher
Acute erythroleukemia (AEL or acute myeloid leukemia [AML]-M6) is a rare but aggressive hematologic malignancy. Previous studies showed that AEL leukemic cells often carry complex karyotypes and mutations in known AML-associated oncogenes. To better define the underlying molecular mechanisms driving the erythroid phenotype, we studied a series of 33 AEL samples representing 3 genetic AEL subgroups including TP53-mutated, epigenetic regulator-mutated (eg, DNMT3A, TET2, or IDH2), and undefined cases with low mutational burden. We established an erythroid vs myeloid transcriptome-based space in which, independently of the molecular subgroup, the majority of the AEL samples exhibited a unique mapping different from both non-M6 AML and myelodysplastic syndrome samples. Notably, >25% of AEL patients, including in the genetically undefined subgroup, showed aberrant expression of key transcriptional regulators, including SKI, ERG, and ETO2. Ectopic expression of these factors in murine erythroid progenitors blocked in vitro erythroid differentiation and led to immortalization associated with decreased chromatin accessibility at GATA1-binding sites and functional interference with GATA1 activity. In vivo models showed development of lethal erythroid, mixed erythroid/myeloid, or other malignancies depending on the cell population in which AEL-associated alterations were expressed. Collectively, our data indicate that AEL is a molecularly heterogeneous disease with an erythroid identity that results in part from the aberrant activity of key erythroid transcription factors in hematopoietic stem or progenitor cells.

3 February 2023 in Blood
Verified
Journal Article
Open access
PDF file
MPMaria-Riera Piqué-Borràs
Maria-Riera Piqué-Borràs
ZJZivojin Jevtic
Zivojin Jevtic
FBFrederik Otzen Bagger
Frederik Otzen Bagger
JSJonathan Seguin
Jonathan Seguin
RSRathick Sivalingam
Rathick Sivalingam
JSJuerg Schwaller
Juerg Schwaller
The NFIA-ETO2 fusion is the product of a t(1;16)(p31;q24) chromosomal translocation so far exclusively found in pediatric patients with pure erythroid leukemia (PEL). To address the role for the pathogenesis of the disease, we expressed the NFIA-ETO2 fusion in murine erythroblasts. We observed that NFIA-ETO2 significantly increased proliferation and impaired erythroid differentiation of murine erythroleuemia (MEL) cells and of primary fetal liver-derived erythroblasts. However, NFIA-ETO2-expressing erythroblasts acquired neither aberrant in vitro clonogenic activity nor disease-inducing potential upon transplantation into irradiated syngenic mice. In contrast, in the presence of one of the most prevalent erythroleukemia-associated mutations, TP53R248Q, expression of NFIA-ETO2 resulted in aberrant clonogenic activity, and induced a fully penetrant transplantable PEL-like disease in mice. Molecular studies support that NFIA-ETO2 interferes with erythroid differentiation by preferentially binding and repressing erythroid genes that contain NFI binding sites and/or are decorated by ETO2, resulting in a activity shift from GATA- to ETS-motif-containing target genes. In contrast, TP53R248Q does not affect erythroid differentiation but provides self-renewal and survival potential, mostly via downregulation of known TP53 targets. Collectively, our work indicates that NFIA-ETO2 initiates PEL by suppressing gene expression programs of terminal erythroid differentiation and cooperates with TP53 mutation to induce erythroleukemia.


30 June 2019 in HemaSphere
Verified
Journal Article
Open access
AFA. Fagnan
A. Fagnan
MBM. Riera Piqué Borràs
M. Riera Piqué Borràs
CIC. Ignacimouttou
C. Ignacimouttou
FBFrederik Otzen Bagger
Frederik Otzen Bagger
CLC.K. Lopez
C.K. Lopez
TMT. Mercher
T. Mercher
Background: Acute erythroid leukemia (AEL) is a subtype of acute myeloid leukemia (AML) characterized by an accumulation of variable proportions of erythroid progenitor cells and myeloblasts. Two subgroups of AEL have been proposed: 1‐pure erythroid leukemia (PEL, AML‐M6b) characterized by an accumulation of > 80% of erythroid progenitors and 2‐AML‐M6a characterized by an accumulation of both myeloid and erythroid progenitors, a group that has now been integrated into myelodysplastic syndrome (MDS) by the 2016 World Health Organization (WHO) classification. Earlier studies indicated that mutations of TP53 and epigenetic modifiers genes (e.g. TET2, DNMT3A) are prevalent alterations in AEL. However, the underlying molecular mechanisms driving the erythroid phenotype remain poorly understood.Aims: The aims of this study were to better characterize the mutational and transcriptional landscape of AEL and to model the functional consequence of these alterations.Methods: We collected AEL patient samples and performed transcriptomic (RNAseq) and genetic (exomes) analyses, on 31 and 11 samples respectively. Candidate alterations were then expressed in mouse erythroid progenitors and hematopoietic stem and progenitor cells (HSPC), in vitro and in in vivo bone marrow (BM) reconstitution assays to obtain functional insights.Results: The genetic landscape grouped patients into at least 3 molecular subgroups: 1‐TP53 mutations (32%), 2‐Epigenetic modifiers (e.g. TET2, DNMT3A) mutations (32%), 3‐Others. Some patients present combinations of mutations that could represent the basis for an erythroid bias. For example, a patient showed TP53 mutation with an out‐of‐frame fusion leading to aberrant EPO overexpression. Another patient presented with a TET2 mutation associated with a GATA1 s mutation previously associated with familial macrocytic anemia and megakaryoblastic leukemia with Down's syndrome. Gene expression signatures indicated that several human AEL samples present with drastic changes in the expression of genes related to GATA1 activity, including ERG, ETO2, SPI1 and SKI. Ectopic expression of these genes through retroviral transduction of mouse erythroblasts led to their immortalization in vitro and, when engrafted thereafter in mice, to leukemia presenting characteristics of AEL. Similarly, purified erythroblasts from a TET2 −/− GATA1 s double transgenic mouse model showed high long‐term proliferation capacity in vitro and subsequent murine AEL. In contrast, transplantation of multipotent progenitors transduced with SKI retrovirus or purified from TET2 −/− GATA1 s double transgenics led to the development of a more myeloid disease, respectively mimicking MDS with erythroid component or more homogeneous myeloid leukemia. Therefore, altered activity of these factors in erythroid progenitors led to pure erythroid phenotypes and to mixed erythroid and myeloid phenotypes upon expression in multipotent progenitors.Summary/Conclusion: We report that, in addition to previously described genetic alterations including TP53 and chromatin regulator mutations, human AEL is also characterized by aberrant expression of several genes interfering with GATA1 including ETS factors, ETO2 and SKI. Modeling their ectopic expression in different murine progenitors suggests that the prevalence of the erythroid phenotype is dependent on the targeted cell type. Together, alterations of the GATA1 transcriptional activity and targeting of different stages of the hematopoietic differentiation may explain the continuum of phenotype between MDS and pure erythroid in human AEL.


4 April 2026
Verified
Thesis
Closed access
AFAlexandre Fagnan
Alexandre Fagnan
Les leucémies aiguës érythroïdes (LAM-M6) représentent un sous-groupe agressif des leucémies aiguës myéloïdes (LAM), affectant la lignée myéloïde et érythroïde. L’objectif de ce travail était de caractériser le profil génétique et transcriptionnel des LAM-M6. Les analyses de séquençage de patients atteints de LAM-M6 m’ont permis d’identifier des altérations génétiques et transcriptionnelles récurrentes. Parmi celles-ci, j’ai identifié des altérations de facteurs impliqués dans l’activité des complexes GATA1 (incluant des surexpressions de SKI, ERG, SPI1 et ETO2) dans plus de 25% des patients. La modélisation de ces altérations en modèle murin m’a permis de démontrer le potentiel oncogénique de ces facteurs, permettant le développement de leucémies myéloïdes et/ou érythroïdes en fonction du progéniteur ciblé. ETO2 est un membre de la famille ETO, fréquemment mutée dans les LAM. La seconde partie de ce travail de thèse était la caractérisation du rôle d’ETO2 dans les LAM-M6. Pour cela, j’ai d’une part montré qu’ETO2 est un facteur essentiel au maintien et à la survie des LAM-M6 humaines. Dans un second temps, j’ai identifié les sites de fixation à la chromatine ainsi que les gènes cibles directs d’ETO2 dans des modèles de xénogreffes dérivés de patients LAM-M6 et de lignées cellulaires inactivées pour ETO2 en utilisant le système CRSPR/Cas9. Ensemble, ces analyses m’ont permis de montrer qu’ETO2 régule un programme oncogénique dont certains membres peuvent être ciblés pharmacologiquement. Ces travaux apportent de nouvelles bases moléculaires concernant le développement des LAM- M6 humaines mais également de nouvelles perspectives de traitement.